AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576

Journal of Alzheimer's Disease

Volumn 4, Issue 5, 2002, Pages 417-430

  Otth, Carola ^a,b   Concha, Ilona I ^a,b   Arendt, Thomas ^c   Stieler, Jens ^c   Schliebs, Reinhard ^c   González Billault, Christian ^a,d   Maccionia, Ricardo B ^a,d  

^a Iniciativa Cientifica Milenio Santiago   (Chile)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Cdk5; Neurodegeneration; Regulatory aspects; Transgenic mouse Tg2576

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIBODY; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; EPITOPE; PROTEIN P25; PROTEIN P35; TAU PROTEIN; NERVE PROTEIN; NEURONAL CDK5 ACTIVATOR (P25 P35); NEURONAL CDK5 ACTIVATOR (P25-P35);

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL CULTURE; CONTROLLED STUDY; DENTATE GYRUS; DEREGULATION; GENE EXPRESSION; GENE MUTATION; GRANULAR CELL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEURITE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BLOTTING, WESTERN; BRAIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PHOSPHORYLATION; TAU PROTEINS;

EID: 0036771832     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2002-4508     Document Type: Article

References (51)

1. M.K. Ahlijanian, N.X. Barrezueta, R.D. Williams, A. Jakowski, K.P. Kowsz, S. McCarthy, T. Coskran, A. Carlo, P.A. Seymour, J.E. Burkhardt, R.B. Nelson and J.D. McNeish, Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5, Proceedings of the National Academy of Science (USA) 97 (2000), 2910-2915.
2. A. Alvarez, J.P. Munoz and R.B. Maccioni, A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons, Experimental Cell Research 264 (2001), 266-274.
3. A. Alvarez, R. Toro, A. Caceres and R.B. Maccioni, Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death, FEBS Letters 459 (1999), 421-426.
4. T. Arendt, M. Holzer, R. Fruth, M.K. Bruckner and U. Gartner, Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A, Neurobiology of Aging 19 (1998), 3-13.
5. J. Busciglio, A. Lorenzo, J. Yeh and B.A. Yankner, Betaamyloid fibrils induce tau phosphorylation and loss of microtubule binding, Neuron 14 (1995), 879-888.
6. P.F. Chapman, G.L. White, M.W. Jones, D. Cooper-Blacketer, V.J. Marshall, M. Irizarry, L. Younkin, M.A. Good, T.V. Bliss, B.T. Hyman, S.G. Younkin, and K.K. Hsiao, Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice, Nature Neuroscience 2 (1999), 271-276.
7. C.W. Cotman, E.R. Whittemore, J.A. Watt, A.J. Anderson and D.T. Loo, Possible role of apoptosis in Alzheimer's disease, Annals N Y Academy of Science 747 (1994), 36-49.
8. D. Games, K.M. Khan, F.G. Soriano, P.S. Keim, D.L. Davis, K. Bryant and I. Lieberburg, Lack of Alzheimer pathology after beta-amyloid protein injections in rat brain, Neurobiology of Aging 13 (1992), 569-576.
9. T. Gomez-Isla, R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, J.E. Parisi and B.T. Hyman, Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease, Annals of Neurology 41 (1997), 17-24.
10. J. Gotz, F. Chen, J. van Dorpe and R.M. Nitsch, Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils, Science 293 (2001), 1491-1495.
11. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang and G. Cole, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science 274 (1996), 99-102.
12. J. Hardy, K. Duff, K.G. Hardy, J. Perez-Tur and M. Hutton, Genetic dissection of Alzheimer's disease and related dementias, amyloid and its relationship to tau, Nature Neuroscience 1 (1998), 355-358.
13. K. Ishiguro, M. Takamatsu, K. Tomizawa, A. Omori, M. Takahashi, M. Arioka, T. Uchida and K. Imahori, Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments, Journal of Biological Chemistry 267 (1992), 10897-10901.
14. K. Imahori and T. Uchida, Physiology and pathology of tau protein kinases in relation to Alzheimer's disease, Journal of Biochemistry (Tokyo) 121 (1997), 179-188.
15. MC. Irizarry, M. McNamara, K. Fedorchak, K. Hsiao and B.T. Hyman, APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CAI, Journal of Neuropathology Experimental Neurology 56 (1997), 965-973.
16. J. Joseph, B. Shukitt-Hale, N.A. Denisova, A. Martin, G. Perry and M.A. Smith, Copernicus revisited, amyloid beta in Alzheimer's disease, Neurobiology of Aging 22 (2001), 131-146.
17. J.Y. Koh, L.L. Yang and C.W. Cotman, Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage, Brain Research 533 (1990), 315-320.
18. K.Y. Lee, A.W. Clark, J.L. Rosales, K. Chapman, T. Fung and R.N. Johnston, Elevated neuronal Cdc-2 like kinase activity in the Alzheimer disease brain, Neuroscience Research 34 (1999), 21-29.
19. M.S. Lee, Y.T. Kwon, M. Li, J. Peng, R.M. Friedlander and L.H. Tsai, Neurotoxicity induces cleavage of p35 to p25 by calpain, Nature 405 (2000), 360-364.
20. J. Lewis, D.W. Dickson, W.L. Lin, L. Chisholm, A. Corral, G. Jones, S.H. Yen, N. Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton and E. McGowan, Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP, Science 293 (2001), 1487-1491.
21. A. Lorenzo and B.A. YankneR, Amyloid fibril toxicity in Alzheimer's disease and diabetes, Annals N Y Academy of Science 777 (1996), 89-95.
22. J.J. Lucas, F. Hernandez, P. Gomez-Ramos, M.A. Moran, R. Hen, J. Avila, Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice, EMBO Journal 20 (2001), 27-39.
23. R.B. Maccioni, J.P. Munoz and L. Barbeito, The molecular bases of Alzheimer's disease and other neurodegenerative disorders, Archives of Medical Research 32 (2001), 367-381.
24. R.B. Maccioni and V. Cambiazo, Role of microtubuleassociated proteins in the control of microtubule assembly, Physiological Reviews 75 (1995), 835-864.
25. R.B. Maccioni, C. Otth, I.I. Concha and J.P. Munoz, The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology, European Journal of Biochemistry 268 (2001), 1518-1527.
26. E.M. Mandelkow, J. Biemat, G. Drewes, N. Gustke, B. Trinczek and E. Mandelkow, Tau domains, phosphorylation, and interactions with microtubules, Neurobiology of Aging 16 (1995), 355-362; discussion 362-353.
27. B.J. Mark, M.A. Lovell, W.R. Markesbery, K. Uchida and M.P. Mattson, A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide, Journal of Neurochemistry 68 (1997), 255-264.
28. M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg and R.E. Rydel, Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity, Journal of Neuroscience 12 (1992), 376-389.
29. G. Mehlhorn, M. Hollborn and R. Schliebs, Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology, International Journal of Developmental Neuroscience 18 (2000), 423-431.
30. G. Michel, M. Mercken, M. Murayama, K. Noguchi, K. Ishiguro, K. Imahori and A. Takashima, Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells, Biochimica et Biophysica Acta 1380 (1998), 177-182.
31. G. Paglini, G. Pigino, P. Kunda, G. Morfini, R. Maccioni, S. Quiroga, A. Ferreira and A. Caceres, Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth, Journal of Neuroscience 18 (1998), 9858-9869.
32. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes and L.H. Tsai, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402 (1999), 615-622.
33. C.J. Pike, D. Burdick, A.J. Walencewicz, C.G. Glabe and C.W. Cotman, Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state, Journal of Neuroscience 13 (1993), 1676-1687.
34. C.J. Pike, M.J. Overman and C.W. Cotman, Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro, Journal of Biological Chemistry 270 (1995), 23895-23898.
35. M. Rapoport, H.N. Dawson, L.I. Binder, M.P. Vitek and A. Ferreira, Tau is essential to beta-amyloid-induced neurotoxicity, Proceedings of the National Academy of Science (USA) 99 (2002), 6364-6369.
36. L.M. Sayre, M.A. Smith and G. Perry, Chemistry and biochemistry of oxidative stress in neurodegenerative disease, Current Medical Chemistry 8 (2001), 721-738.
37. L.M. Sayre, D.A. Zelasko, P.L. Harris, G. Perry, R.G. Salomon and M.A. Smith, 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease, Journal of Neurochemistry 68 (1997), 2092-2097.
38. O. Schweers, E.M. Mandelkow, J. Biemat and E. Mandelkow, Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments, Proceedings of the National Academy of Science (USA) 92 (1995), 8463-8467.
39. D.J. Selkoe, Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease, Annual Review of Cell Biology 10 (1994), 373-403.
40. D.J. Selkoe, Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399 (1999), A23-31.
41. A. Sengupta, Q. Wu, I. Grundke-Iqbal, K. Iqbal and T.J. Singh, Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5, Molecular Cellular Biochemistry 167 (1997), 99-105.
42. M.G. Spillantini and M. Goedert, Tau protein pathology in neurodegenerative diseases, Trends in Neuroscience 21 (1998), 428-433.
43. B. Stein-Behrens, K. Adams, M. Yeh and R. Sapolsky, Failure of beta-amyloid protein fragment 25-35 to cause hippocampal damage in the rat, Neurobiology of Aging 13 (1992), 577-579.
44. A. Takashima, K. Noguchi, K. Sato, T. Hoshino and K. Imahori, Tau protein kinase I is essential for amyloid beta-proteininduced neurotoxicity, Proceedings of the National Academy of Science (USA) 90 (1993), 7789-7793.
45. D. Tang, K.Y. Lee, Z. Qi, I. Matsuura and J.H. Wang, Neuronal Cdc2-like kinase: From cell cycle to neuronal function, Biochemical Cell Biology 74 (1996), 419-429.
46. Y. Tomidokoro, Y. Harigaya, E. Matsubara, M. Ikeda, T. Kawarabayashi, T. Shirao, K. Ishiguro, K. Okamoto, S.G. Younkin and M. Shoji, Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau, Journal of Pathology 194 (2001), 500-506.
47. Y. Tomidokoro, K. Ishiguro, Y. Harigaya, E. Matsubara, M. Ikeda, J.M. Park, K. Yasutake, T. Kawarabayashi, K. Okamoto and M. Shoji, Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice, Neuroscience Letters 299 (2001), 169-172.
48. H. Towbin, T. Staehelin and J. Gordon, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets, procedure and some applications, Proceedings of the National Academy of Science (USA) 76 (1979), 4350-4354.
49. L.H. Tsai, I. Delalle, V.S. Caviness, T. Chae, Jr. and E. Harlow, p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5, Nature 371 (1994), 419-423.
50. K. Uryu, H. Laurer, T. McIntosh, D. Pratico, D. Martinez, S. Leight, V.M. Lee and J.Q. Trojanowski. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis, Journal of Neuroscience 22 (2002), 446-454.
51. A. Yamamoto, J.J. Lucas and R. Hen, Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000), 57-66.